ACADIA PHARMACEUTICALS INC — Form 8-K
Filed September 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Acadia announced Phase 2 RADIANT results for remlifanserin (ADP treatment): 60 mg once-daily narrowly missed primary endpoint SAPS-H+D (p=0.0603, effect size 0.26) but achieved statistical significance on key secondary endpoint CGI-S-ADP (p=0.0077, effect size 0.37). Company will continue Phase 3 development with 60 mg dose, removing the 30 mg arm; safety profile was favorable with no QT prolongation signal.
Why this rating
Mixed Phase 2 results (missed primary, hit secondary) in mid-stage pipeline program create moderate uncertainty. No immediate revenue impact, but outcome matters for long-term pipeline value. Relative to $2.3B market cap, this is a meaningful but not transformational development.
See more from September 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.